|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
3 April 2023 |
|
Main ID: |
NCT02284308 |
|
Date of registration:
|
30/10/2014 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Elderly With Locally Advanced Lung Cancer: Deciding Through Geriatric Assessment on the Optimal Treatment Strategy
ELDAPT |
|
Scientific title:
|
ELDAPT: Elderly With Locally Advanced Lung Cancer: Deciding Through Geriatric Assessment on the oPtimal Treatment Strategy |
|
Date of first enrolment:
|
July 2016 |
|
Target sample size:
|
288 |
|
Recruitment status: |
Recruiting |
|
URL:
|
https://clinicaltrials.gov/show/NCT02284308 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
Belgium
|
Netherlands
| | | | | | |
|
Contacts
|
|
Name:
|
Anne-Marie Dingemans, MD, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Erasmus Medical Center |
|
|
Name:
|
Mariska Janssen-Heijnen, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
VieCuri Medical Centre |
|
|
Name:
|
Judith van Loon, MD, PhD |
|
Address:
|
|
|
Telephone:
|
+31 88 44 55 600 |
|
Email:
|
judith.vanloon@maastro.nl |
|
Affiliation:
|
|
|
|
Name:
|
Judith van Loon, MD, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Maastro (radiotherapist) |
| | |
|
Key inclusion & exclusion criteria
|
- Any subtype of pathologically proven NSCLC, primary UICC Stage III disease;
- Age = 75 years;
- No surgery or adjuvant chemotherapy for NSCLC in the last year;
- No prior radiotherapy to the ipsilateral thorax or mediastinum;
- No clinical superior vena cava syndrome;
- No diagnosis of other cancer within the last 3-years (except in situ carcinoma's and /
or non-melanoma skin cancer);
- Written informed consent
Age minimum:
75 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
NSCLC
|
|
Primary Outcome(s)
|
|
Correlation GA with QAS (quality adjusted survival)
[Time Frame: 5 years]
|
|
Secondary Outcome(s)
|
|
Cost-effectiveness
[Time Frame: End of study]
|
|
Predictive value
[Time Frame: 5 years]
|
|
Medical comparison between treatments
[Time Frame: 5 years]
|
|
Development and validation of geriatric screening instrument
[Time Frame: 5 years]
|
|
Flow chart
[Time Frame: 5 years]
|
|
Geriatric assessment
[Time Frame: Baseline]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|